Recent performance snapshot

Relay Therapeutics (RLAY) has traded under pressure recently, with the stock down about 28% over the past month. It remains up roughly 33% over the past 3 months and 48% year to date.

Relay Therapeutics’ share price has pulled back recently, with a 7 day share price return of down 6.65% and a 30 day share price return of down 27.98%. However, the year to date share price return of 47.55% and a 1 year total shareholder return of very large magnitude suggest momentum has shifted from a strong upswing to a period of cooling.

If you are looking beyond a single biotech stock, this is a good moment to see what else is moving in healthcare focused AI using our 29 healthcare AI stocks

With Relay Therapeutics posting US$10.68m in revenue alongside a US$272.71m net loss and trading at a market value of about US$2.32b, some investors may question whether the recent weakness presents an entry point or whether the market is already pricing in potential future growth.

Price to book check: Is Relay Therapeutics’ premium justified?

Relay Therapeutics trades at a P/B ratio of 3.6x, which sits above the broader US biotech sector but below its closer peer group.

The P/B ratio compares the company’s market value with its accounting book value, so a higher figure often reflects investor willingness to pay more for each dollar of net assets. For a clinical stage biotech that is still loss making, P/B can also reflect expectations around the pipeline and potential future revenue rather than current earnings.

In this case, the 3.6x P/B is described as expensive relative to the US biotech industry average of 2.3x, which suggests the stock trades at a premium to the wider sector. At the same time, it is considered good value against a closer peer set that sits around 7.6x, which points to investors assigning Relay Therapeutics a lower multiple than some comparable companies despite similar business characteristics.

Result: Price-to-book of 3.6x (ABOUT RIGHT)

However, you also need to weigh the ongoing US$272.71m net loss and early stage pipeline risk, as clinical or partnership setbacks could quickly challenge the current premium.

Next Steps

With sentiment mixed after such a sharp swing in the share price, it makes sense to review the numbers yourself and quickly decide how the balance of risks and rewards stacks up using our 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with a single stock. Use the Simply Wall St screener to quickly spot fresh ideas that match how you like to invest.

• Zero in on potential bargains by checking companies that combine quality, cash flows, and appealing prices through our 54 high quality undervalued stocks.
• Prioritise resilience by focusing on companies that pair strong finances with reduced risk using the 66 resilient stocks with low risk scores.
• Get ahead of the crowd by scanning for overlooked opportunities with robust fundamentals via the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.